{"Clinical Trial ID": "NCT01299038", "Intervention": ["INTERVENTION 1:", "Rosuvastatin 20mg", "Rosuvastatin 20 mg taken orally once daily for 4 weeks", "Rosuvastatin: taken orally once daily for 4 weeks", "INTERVENTION 2:", "Rosuvastatin 40mg", "Rosuvastatin 40 mg taken orally once daily for 4 weeks", "Rosuvastatin: taken orally once daily for 4 weeks"], "Eligibility": ["Incorporation criteria:", "- Metastatic breast adenocarcinoma (Stage IV)", "\u2022 Active endocrine therapy for at least 6 weeks (with or without HER2)", "Minimum age of 18", "ECOG Performance status of 0, 1 or 2", "Normal function of the organ and marrow as defined in the protocol", "- Exclusion criteria:", "The participants may not receive any other study officers.", "\u2022 Receives active chemotherapy (excluding hormonal treatment or HER2) in the last 5 weeks", "Any treatment with statin in the last 3 weeks", "Of decent Asian origin (including Filipino, Chinese, Japanese, Korean, Vietnamese or Asian-Indian)", "Concomitant use of cyclosporin, fibrates, niacin, gemfibrozil, ketaconazole, spironolactone, cimetidine, warfarin, erythromycin or protease inhibitors", "Conditions predisposing to renal failure secondary to rhabdomyolysis", "A recent history of excessive alcohol consumption, as judged by the treating physician", "Known to be pregnant (test not required) or breast-feeding", "History of rhabdomyolysis in statin treatment", "\u2022 Known history of hepatitis C or active hepatitis B infection (basic test not required)", "\u2022 Uncontrolled intercurrent disease including, but not limited to, continuous or active infection, hepatitis, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, or psychiatric or social conditions that would limit compliance with study requirements"], "Results": ["Performance measures:", "Average variation in tissue factor rolling microparticles", "Comparison of plasma concentrations of microparticles between early and week 4", "Duration: 4 weeks", "Results 1:", "Title of the arm/group: Rosuvastatin 20mg", "Description of the arm/group: Rosuvastatin 20mg taken orally once daily for 4 weeks", "Rosuvastatin: taken orally once daily for 4 weeks", "Total number of participants analysed: 8", "Average (standard deviation)", "Unit of measurement: microparticles per microlitre 102 (586)", "Results 2:", "Title of the arm/group: Rosuvastatin 40mg", "Description of the arm/group: Rosuvastatin 40mg taken orally once daily for 4 weeks", "Rosuvastatin: taken orally once daily for 4 weeks", "Total number of participants analysed: 7", "Average (standard deviation)", "Unit of measurement: microparticles per microlitre -618 (624)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/9 (0.00 per cent)", "Adverse Events 2:", "Total: 0/10 (0.00 per cent)"]}